News

The FDA has approved its supplemental New Drug Application for Wakix tablets for the treatment of excessive daytime sleepiness in pediatric patients aged 6 years and older with narcolepsy.

Additionally, 27% of US adults have reported they have a disability across a spectrum of areas.

Do we need a potential classification of social psychoexemplaries?

Here are highlights from the week in Psychiatric Times.

The FDA has authorized the marketing of 4 menthol-flavored e-cigarette products in the United States through the premarket tobacco product application pathway.

What role does countertransference play in physician-assisted suicide? Learn more here.

Recent research found approximately 60 documented cases of suicidal ideation and 7 suicide attempts associated with semaglutide use in patients.

"Of all the questions you might want to ask about angels, the only one you ever hear is how many can dance on the head of a pin..."

When is forgiveness not enough?

Children are subject to the world’s largest biosocial experiment.

The outcomes of this study are expected to inform the development of the upcoming PATHFINDER-52 phase 2b clinical trial.

In this CME article, read more about best practices for utilizing clozapine plasma levels and the clozapine/norclozapine ratio to monitor clozapine therapy.

ALTO-101 has previously been shown to positively impact cognition in schizophrenia.

Cannabis withdrawal syndrome impacts approximately half of those who use it regularly. How can you help patients cease cannabis use?

Yesterday, we celebrated Juneteenth.

Are we ready for summer?

How can artificial intelligence enhance psychiatry certification, and how do we implement it?

Review tapering challenges and strategies for benzodiazepines in this Special Report article.

Check out the latest results from the phase 3 CONNEX-X study.

Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints, according to new study.

Validating some patients could lead to both clinician and patient harm.

How can we mitigate climate issues without harming working Americans?

Laughter: the best medicine?

In this Special Report, get the latest from the American Psychiatric Association Annual Meeting!

Review the multiple uses of metformin.

How do you define heroism? Who is a modern hero?

Here are highlights from the week in Psychiatric Times.

What is their comparative safety?

The CDC suggests that disrupted access to ADHD medications may increase risk of overdose and injury.

Do physical health conditions in childhood affect ADHD symptoms at age 17 years? Researchers investigated these associations in a large cohort study.